ARTICLE | Company News

EPO revokes Forward patent related to Tecfidera

February 2, 2018 8:26 PM UTC

Forward Pharma A/S (NASDAQ:FWP) said the European Patent Office revoked Forward's European Patent No. EP2801355, which Forward claims is infringed by blockbuster multiple sclerosis drug Tecfidera dimethyl fumarate from Biogen Inc. (NASDAQ:BIIB). The company told BioCentury it expects EPO to issue its detailed reasons within three months, after which it plans to appeal the decision.

If EPO rules in favor of Forward following the appeals process, the company will be eligible for royalties on ex-U.S. sales of Tecfidera of 10% in 2021-2028 and 20% starting in 2029. If the company’s appeal fails it will not be eligible for royalties...